Clinical trial
Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head…
NCT00319839 · University of California, Irvine, Other · Terminated
Key facts
| NCT number | NCT00319839 |
|---|---|
| Title | Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab |
| Official title | A Phase II Study of Albumin Bound-Paclitaxel (AbraxaneTM) for Treatment of Recurrent or Metastatic Head and Neck Cancer With the Addition of Cetuximab (Erbitux) (IMC-225) on Disease Progression |
| Lead sponsor | University of California, Irvine, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Abraxane, Cetuximab |
| Enrollment | 10 |
| Start date | Mar 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | Jun 1, 2010 |
| First posted | Apr 27, 2006 |
| Last update posted | Jan 12, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: